piscesCSM: prediction of anticancer synergistic drug combinations

被引:0
|
作者
AlJarf, Raghad [1 ,2 ,3 ]
Rodrigues, Carlos H. M. [1 ,2 ,3 ,4 ]
Myung, Yoochan [1 ,2 ,3 ,4 ]
Pires, Douglas E. V. [2 ,3 ,5 ]
Ascher, David B. [1 ,2 ,3 ,4 ]
机构
[1] Univ Melbourne, Dept Biochem & Pharmacol, Struct Biol & Bioinformat, Melbourne, Vic, Australia
[2] Univ Melbourne, Bio21 Inst, Syst & Computat Biol, Melbourne, Vic, Australia
[3] Baker Heart & Diabet Inst, Computat Biol & Clin Informat, Melbourne, Vic, Australia
[4] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia
[5] Univ Melbourne, Sch Comp & Informat Syst, Melbourne, Vic, Australia
来源
JOURNAL OF CHEMINFORMATICS | 2024年 / 16卷 / 01期
基金
英国医学研究理事会;
关键词
Drug combination; Machine learning; Graph-based signatures; Synergistic effects; Anticancer drugs; GRAPH-BASED SIGNATURES; MUTATIONS; TOXICITY; IDENTIFY; SERVER;
D O I
10.1186/s13321-024-00859-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
While drug combination therapies are of great importance, particularly in cancer treatment, identifying novel synergistic drug combinations has been a challenging venture. Computational methods have emerged in this context as a promising tool for prioritizing drug combinations for further evaluation, though they have presented limited performance, utility, and interpretability. Here, we propose a novel predictive tool, piscesCSM, that leverages graph-based representations to model small molecule chemical structures to accurately predict drug combinations with favourable anticancer synergistic effects against one or multiple cancer cell lines. Leveraging these insights, we developed a general supervised machine learning model to guide the prediction of anticancer synergistic drug combinations in over 30 cell lines. It achieved an area under the receiver operating characteristic curve (AUROC) of up to 0.89 on independent non-redundant blind tests, outperforming state-of-the-art approaches on both large-scale oncology screening data and an independent test set generated by AstraZeneca (with more than a 16% improvement in predictive accuracy). Moreover, by exploring the interpretability of our approach, we found that simple physicochemical properties and graph-based signatures are predictive of chemotherapy synergism. To provide a simple and integrated platform to rapidly screen potential candidate pairs with favourable synergistic anticancer effects, we made piscesCSM freely available online at https://biosig.lab.uq.edu.au/piscescsm/ as a web server and API. We believe that our predictive tool will provide a valuable resource for optimizing and augmenting combinatorial screening libraries to identify effective and safe synergistic anticancer drug combinations. Scientific contribution This work proposes piscesCSM, a machine-learning-based framework that relies on well-established graph-based representations of small molecules to identify and provide better predictive accuracy of syngenetic drug combinations. Our model, piscesCSM, shows that combining physiochemical properties with graph-based signatures can outperform current architectures on classification prediction tasks. Furthermore, implementing our tool as a web server offers a user-friendly platform for researchers to screen for potential synergistic drug combinations with favorable anticancer effects against one or multiple cancer cell lines.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Prediction of synergistic anticancer drug combinations by integrating chemical and genetic screens
    Jaiswal, Alok
    Gautam, Prson
    Tang, Jing
    Wennerberg, Krister
    Aittokallio, Tero
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [2] Deep graph embedding for prioritizing synergistic anticancer drug combinations
    Jiang, Peiran
    Huang, Shujun
    Fu, Zhenyuan
    Sun, Zexuan
    Lakowski, Ted M.
    Hu, Pingzhao
    [J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 : 427 - 438
  • [3] Synergistic drug combinations prediction by integrating pharmacological data
    Zhang, Chengzhi
    Yan, Guiying
    [J]. SYNTHETIC AND SYSTEMS BIOTECHNOLOGY, 2019, 4 (01) : 67 - 72
  • [4] SYNERGISTIC ONCOLYTIC DRUG-COMBINATIONS INVOLVING DIDOX(DD) A NEW ANTICANCER DRUG
    ELFORD, HL
    VANTRIET, B
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 325 - 325
  • [5] SYNERGISTIC ONCOLYTIC DRUG-COMBINATIONS INVOLVING DIDOX A NEW ANTICANCER DRUG - (AN UPDATE)
    ELFORD, HL
    VANTRIET, B
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 374 - 374
  • [6] Predicting anticancer synergistic drug combinations based on multi-task learning
    Chen, Danyi
    Wang, Xiaowen
    Zhu, Hongming
    Jiang, Yizhi
    Li, Yulong
    Liu, Qi
    Liu, Qin
    [J]. BMC BIOINFORMATICS, 2023, 24 (01)
  • [7] Predicting anticancer synergistic drug combinations based on multi-task learning
    Danyi Chen
    Xiaowen Wang
    Hongming Zhu
    Yizhi Jiang
    Yulong Li
    Qi Liu
    Qin Liu
    [J]. BMC Bioinformatics, 24
  • [8] Predicting Synergistic Effect of Anticancer Drug Combinations Based on Nuclear Norm Regularization
    Shi Lei-Jing
    Wang Bo
    Zhang Shan
    Ren Fu-Quan
    Li Yu-Shuang
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2023, 50 (03) : 634 - 646
  • [9] Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics
    Li, Shiqi
    Zhang, Fuhui
    Xiao, Xiuchan
    Guo, Yanzhi
    Wen, Zhining
    Li, Menglong
    Pu, Xuemei
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] DFFNDDS: prediction of synergistic drug combinations with dual feature fusion networks
    Mengdie Xu
    Xinwei Zhao
    Jingyu Wang
    Wei Feng
    Naifeng Wen
    Chunyu Wang
    Junjie Wang
    Yun Liu
    Lingling Zhao
    [J]. Journal of Cheminformatics, 15